New gout drug offers hope for those who have exhausted treatment options
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva’s acquisition of Barr. In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product
Full Post: Teva and Barr receive European approval for acquisition
Researchers in the U.S. say a new drug effectively treats serious cases of gout - the drug called pegloticase mimics a blood-clearing enzyme missing in humans and helps remove the build up in uric acid, which causes the painful, needle-like crystals to collect around fingers, toes and other joints.
Pegloticase made by the Savient Pharmaceuticals, has successfully completed a phase III trial - the last stage of human testing - which must be done prior to applying for U.S. Food and Drug Administration approval.
The trial showed that uric acid levels fell to target levels among all patients who were given it intravenously, within six hours and in 40% of the cases one infusion kept levels down for at least six months.
Dr. John Sundy, a rheumatologist at Duke University Medical Center in North Carolina, who led the study, says there have been no new drugs for gout for 40 years and there are 50,000 patients in the U.S. alone who will benefit.
Most gout patients are treated with the drug allopurinol but some sufferers don’t respond to it or cannot tolerate it and they might benefit from a new therapeutic option.
Gout has often been presented as a disease of men who eat and drink too much, and while it can have links with lifestyle, the disease also has genetic causes.
An estimated 2 million to 3 million people in the United States have the condition.
Dr. Sundy says a typical patient is male, probably in his 40s or 50s, who suddenly develops searing pain in one of his big toes.
The infusions had some side effects however, including back or chest pain, chills, nausea and headaches - Savient Pharmaceuticals is hoping to license the drug under the brand name Puricase.
For the trial the patients, mostly men with an average age of 55 years, were randomly assigned to receive six months of intravenous treatment with either pegloticase or a placebo.
One group of patients received 8 milligrams of pegloticase every two weeks, another group received 8 milligrams of pegloticase every four weeks, and a third group received the placebo.
The researchers say the patients on pegloticase had a significantly better response than those on the placebo and those taking pegloticase also noticed improved physical function.
Dr. Sundy says people with gout suffer from severe pain, increased disability, and reduced quality of life and for those with gout who have exhausted all available treatment options, these findings are exciting.
The researchers presented their findings at the American College of Rheumatology annual meeting, in San Francisco.
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted the Company’s BLA with a priority review status which accelerates the review period to six months. A
Full Post: Pegloticase BLA filing accepted for priority review by FDA
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of
Full Post: Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout
XTL Biopharmaceuticals Ltd. has announced the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial’s primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in
Full Post: XTL Biopharmaceuticals announces results from Bicifadine in diabetic neuropathic pain trial
Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. CP is a progressive inflammatory disease of the pancreas in which patients experience abdominal pain (in early stage) and diabetes and maldigestion (in late stage). Pain is
Full Post: Antioxidant supplementation effective in relieving pain in chronic pancreatitis
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that “durable pain palliation is an acceptable and desirable study endpoint” to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Full Post: OncoGenex achieves key regulatory milestone for lead product candidate